Receptor-directed therapy of T-cell leukemias and lymphomas.
T-Cell leukemias and lymphomas represent a less common and heterogeneous group of lymphoid neoplasms. Overall, they respond less well to chemotherapy and have a poorer prognosis than their B-cell counterparts. T-Cell tumors express a number of potential targets for receptor-directed antibody therapy; however, there is no available therapeutic monoclonal antibody for these diseases with comparable activity to that of rituximab in B-cell disorders. Despite this, alemtuzumab, a humanized anti-CD52 monoclonal antibody has demonstrated meaningful anti-tumor activity in a variety of T-cell malignancies. A number of other antibodies, modified antibodies and immunotoxins directed against targets such as CD2, CD4, CD5, CD25, CD30 and CD122 expressed on malignant T-cells are under investigation. The current status of receptor-directed antibody therapy for T-cell leukemia and lymphoma is reviewed.
Metabolism Branch, Center for Cancer Research, National Cancer Institute, Mark O. Hatfield Clinical Research Center, Bethesda, Maryland 20892-1457, USA. jmorris@mail.nih.gov
John C
JC
Morris
Thomas A
TA
Waldmann
John E
JE
Janik
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015458:Leukemia, T-Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D016399:Lymphoma, T-Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors* / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000970:Antineoplastic Agents; D011956:Receptors, Cell Surface; D000074323:Alemtuzumab